Galderma to showcase the latest data on its diverse and science-based aesthetics portfolio at the 2024 Aesthetic & Anti-Aging Medicine World Congress (AMWC). Across 16 e-posters – including data from its diverse range of fillers (Restylane®), leading neuromodulator portfolio (RelabotulinumtoxinA*, Alluzience® and Dysport®) and original biostimulator (Sculptra®) – Galderma will demonstrate its commitment to delivering experiences that are tailored to the individual needs of healthcare professionals and patients.
Details on the scientific presentations supported by Galderma at AMWC 2024 can be found below.
|
First author |
Abstract title |
|
A. Nikolis |
Effectiveness and Safety of a New NASHA-HD Hyaluronic Acid Injectable, HASHA, for Augmentation and Correction of Chin Retrusion
|
|
R. Ren |
Midface Augmentation in Chinese Subjects Using a Flexible Hyaluronic Acid Filler Evaluated in a Randomized No-treatment Controlled Study
|
|
C. Di Gregorio |
25+ Years of Experience with the Restylane Portfolio of Injectable Hyaluronic Acid Fillers for Facial Aesthetic Treatment
|
|
B. Biesman |
A Study Evaluating the Safety and Effectiveness of Hyaluronic Acid Filler HAEYE for Correction of Infraorbital Hollows (IOH, Tear Trough Study)
|
|
M. Gold |
Subject-Reported Improvement in Well-Being and High Satisfaction After Glabellar Line Treatment with RelabotulinumtoxinA*, an Investigational Ready-to-Use Liquid Botulinum Toxin (READY-1 Phase III Trial)
|
|
L. Grunebaum |
Improved Well-Being and Natural-Looking Results After Treatment of Lateral Canthal Lines with RelabotulinumtoxinA*, an Investigational Liquid Botulinum Toxin (READY-2 Phase III Trial)
|
|
C. Persson |
An Economic Model for a Recently Introduced Ready-to-Use Liquid Formulation of AbobotulinumtoxinA
|
|
J. Huang |
A Real-World Study of Subject and Physician Satisfaction with AbobotulinumtoxinA Treatment of Glabellar Lines in Chinese Subjects
|
|
A. Haddad |
Utilizing the AART™ Methodology to Maximize Aesthetic Treatment Outcomes Using Poly-L-Lactic Acid (PLLA-SCA) Across Different Patient Profiles
|
|
K. Durairaj |
A Multi-Center, Retrospective, Chart Review to Evaluate the Safety of Poly-L-Lactic Acid Injectable Implant When Used in Non-facial Areas
|
|
K. Beleznay |
Safety and Effectiveness of Poly-L-Lactic Acid (PLLA-SCA) for the Improvement in Appearance of Cellulite – A Pilot Study
|
|
J. Joseph |
Evaluation of the Safety and Effectiveness of Higher Reconstitution Volumes of Poly-L-Lactic Acid (PLLA-SCA) for Correction of Wrinkles in the Décolletage Area |
|
B. LaTowsky |
Long-Term Effect of Biostimulatory Sculptra Poly-L-Lactic Acid Injectable (PLLA-SCA) Implant on Correction of Cheek Wrinkles and Nasolabial Fold Contour Deficiencies
|
|
P. Sarlos |
Effectiveness of Poly-L-lactic acid (PLLA-SCA) for the Treatment of Facial Weight Loss Associated with Semaglutide in Patients with Overweight or Obesity
|
|
C. Martschin |
Development of a Novel Skin Quality Assessment Scale (SQS)
|
|
A. Nikolis |
The AART-HIT™ Methodology: A Novel and Systematic Approach of Combining Aesthetic Products to Maximize Patient Outcomes
|
All authors are paid consultants or employees of Galderma.
*RelabotulinumtoxinA is an investigational product and has not received approval for any indication in any country.